Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for InflaRx N.V. (IFRX : NSDQ)

• Company Description    InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. Number of Employees: 74

• Price / Volume Information    Yesterday's Closing Price: $1.05 Daily Weekly Monthly 20 Day Moving Average: 882,977 shares Shares Outstanding: 67.13 (millions) Market Capitalization: $70.49 (millions) Beta: 1.46 52 Week High: $2.77 52 Week Low: $0.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.32% -18.41% 12 Week -23.36% -25.55% Year To Date -57.49% -64.80%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL WINZERLAER STR. 2 - JENA,2M 07745 DEU ph: 49-36-4150-8180 fax: 49-36-4150-8181 ir@inflarx.com http://www.inflarx.de

• General Corporate Information    Officers Niels Riedemann - Chief Executive Officer Nicolas Fulpius - Chairman Thomas Taapken - Chief Financial Officer Renfeng Guo - Director Mark Kubler - Director Peer Information InflaRx N.V. (CORR.) InflaRx N.V. (RSPI) InflaRx N.V. (CGXP) InflaRx N.V. (BGEN) InflaRx N.V. (GTBP) InflaRx N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N44821101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 67.13 Most Recent Split Date: (:1) Beta: 1.46 Market Capitalization: $70.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.75 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.33 Price/Cash Flow: - Price / Sales: 381.03 EPS Growth vs. Year Ago Period: 51.52% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: -79.41% vs. Previous Quarter: -37.78% ROE 09/30/25 - -63.72 06/30/25 - -71.76 03/31/25 - -64.17 ROA 09/30/25 - -49.40 06/30/25 - -57.68 03/31/25 - -53.39 Current Ratio 09/30/25 - 3.33 06/30/25 - 4.10 03/31/25 - 5.28 Quick Ratio 09/30/25 - 3.06 06/30/25 - 3.78 03/31/25 - 4.86 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - -61,241.09 06/30/25 - -27,386.74 03/31/25 - -33,646.85 Book Value 09/30/25 - 0.79 06/30/25 - 0.96 03/31/25 - 1.11 Inventory Turnover 09/30/25 - 0.88 06/30/25 - 0.73 03/31/25 - 0.38 Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©